Skip to main content
Skip to main navigation menu
Skip to site footer
Open Menu
International Journal of Vaccine Theory, Practice, and Research
Home
About
About the Journal
Submissions
Contact
Editorial Board
Privacy Statement
Donate to IJVTPR
Announcements
Current
Archives
Search
Register
Login
Home
/
Archives
/
Vol. 3 No. 1 (2023): Injuries, Causes, & Treatments
Vol. 3 No. 1 (2023): Injuries, Causes, & Treatments
cover for volume 3 issue 1 Injuries, Causes, & Treatments
DOI:
https://doi.org/10.56098/ijvtpr.v3i1
Published:
2023-01-12
Articles
Adjuvant Activity and Toxicological Risks of Lipid Nanoparticles Contained in the COVID‑19 “mRNA Vaccines”
Gabriele Segalla
1085-1102
PDF
Perceived Experience in Social Circles with COVID-19 Injections and COVID-19 “Vaccine” Mandates: An Online Survey of the United States Population
Mark Skidmore, Fernanda Alfaro
1055-1084
PDF
How Many Deaths Can Statistically Be Attributed to Anti-SARS-CoV-2 Injections? An Analysis of German Health Data from 2021
Falk Mörl, Michael Günther, Robert Rockenfeller
1026-1054
PDF
A Finnish Survey of Adverse Effects of COVID-19 Injectables and the Functionality of the Medical System
Tamara Tuuminen, MD, PhD, Adj Prof, Pasi J. Suominen, Tore A. Gulbrandsen, MSc
1009-1025
Tuuminen et al. text in PDF
Forensic analysis of the 38 subject deaths in the 6-Month Interim Report of the Pfizer/BioNTech BNT162b2 mRNA Vaccine Clinical Trial
Corinne Michels, Daniel Perrier, Jeyanthi Kunadhasan, Ed Clark, Joseph Gehrett, Barbara Gehrett, Kim Kwiatek, Sarah Adams, Robert Chandler, Leah Stagno, Tony Damian, Erika Delph, Chris Flowers
973-1008
PDF
Apparent Cytotoxicity and Intrinsic Cytotoxicity of Lipid Nanomaterials Contained in a COVID-19 mRNA Vaccine
Gabriele Segalla
957-972
PDF
The Canaries in the Human DNA Mine
Julian Gillespie
929-956
PDF
Assessment of Comirnaty Injections of Pregnant Women in the Manufacturer’s Risk Management Plan and by the European Medicines Agency: Mandatory Injections for Caregivers in France
Jérôme Sainton
911-928
PDF
Safety of mRNA Vaccines Administered During the First Twenty-Four Months of the International COVID-19 Vaccination Program
Eliana Romero, Shawn Fry, Brian Hooker
891-910
PDF
Abnormal Clots and All-Cause Mortality During the Pandemic Experiment: Five Doses of COVID-19 Vaccine Are Evidently Lethal to Nearly All Medicare Participants
Daniel Santiago, John W Oller
847-890
PDF
Supplementary Files for Santiago & Oller
Source Data for Statistical Analyses
John Oller; CDC and Medicare US and Connecticut
Laboratory testing for COVID-19
Emergency Response Technical Centre NIVD under China CDC
846.1-846.57
PDF
Response to Comments on Kämmerer, et al. (2023) regarding RT-PCR Testing
Ulrike Kämmerer, Sona Pekova, Rainer J. Klement, Rogier Louwen, Pieter Borger, Klaus Steger
846.5-846.9
PDF
Comments on Kämmerer, et al. (2023) regarding RT-PCR Testing
Fabio Franchi, Jerneja Tomsic
846.1-846.4
PDF
RT-PCR Test Targeting the Conserved 5'-UTR of SARS-CoV-2 Overcomes Shortcomings of the First WHO-Recommended RT-PCR Test
Ulrike Kämmerer, Sona Pekova, Rainer Klement, Rogier Louwen, Pieter Borger, Klaus Steger
818-846
PDF
Chemical-physical criticality and toxicological potential of lipid nanomaterials contained in a COVID-19 mRNA vaccine
Gabriele Segalla
787-817
PDF
A 6-Week Time Period May not be Sufficient to Identify Potential Adverse Events Following COVID-19 Vaccination
Hélène Banoun, Patrick Provost
771-812
PDF
Emergence of a New Creutzfeldt-Jakob Disease: 26 Cases of the Human Version of Mad-Cow Disease, Days After a COVID-19 Injection
Jean-Claude Perez, Claire Moret-Chalmin, Luc Montagnier
727-770
PDF
The Blind Spot in COVID-19 Vaccination Policies: Under-Reported Adverse Events
Patrick Provost
707-726
PDF
Injuries, Causes, & Treatments, IJVTPR 3(1): For “Such a Time as This”
John W. Oller
687-706
PDF
Information
For Readers
For Authors
For Librarians
Language
English